XBIO - Long (100 Shares) - RSI Divergence confirmed with 8&20SMA cross up. Huge buy volume on the divergence compared to average volume (very low volume instrument) Entry - 11.18 SL - $8.53 (Last week's low) TP - $19.91 (200SMA) Net Risk - $265 R/R - 3.3
AVROBIO got a good pop today from very positive Phase 2 clinical trial results from its kidney drug. Unquestionably the news was good; the drug shows strong efficacy and no adverse events. However, this was only a Phase 2 trial so there's a long way still to go in the approval process. Meanwhile, the company is losing money and is rated as an overvalued and...
Investors bought the hype surrounding SOLY's clinical trial results, and today they sold the news. SOLY fell nearly 14% despite better-than-expected results in its cellulite treatment trial. Looking at the volume profile, I think SOLY may continue to fall to the 14.00-14.50 range, and then rebound upward from there. I wouldn't enter any earlier than that.
NEOS - Long (500 Shares) Entry - $1.67 SL - $1.37 - Yesterday's low TP - 2.27 Net Risk - $683.33 R/R - 2
The skills and knowledge we apply in currencies can also be applied in any other market, how so?, as long as there is a chart, technical analysis can be used to predict and/or determine future movements, along with fundamentals and economic events. Here is a possible investment opportunity for those interested in owning shares. Good Luck ;)
Syros Pharmaceuticals made a big move up this morning, but has retraced to support at 7.08 (not reflected on the chart yet for some reason). It may bounce higher later today.
Arvinas Pharmaceuticals is on a run thanks to FDA approval of phase 1 clinical trials on a new drug. It's above critical resistance levels and appears to have clearance up to 25.60. Personally I won't be taking a position in this one, though. Arvinas's earnings are pretty garbage, and honestly a phase 1 clinical trial doesn't mean much in this industry. We've...
It sounds like the trade war between USA and China is about to get resolved. IF it does I expect a move higher for the markets. With LABU sitting on lower support, it should be a short term low risk BUY.
ITCI is moving mostly horizontally lately, and there's definite room for downside to its channel bottom around 10.40, so this is a risky play. However, a large stock purchase a couple days ago by one of the board of directors triggered a large volume of bullish option activity. Possibly the director purchased stock in anticipation of forthcoming clinical trial...
Pieris is in an upward channel and looking bullish. Analyst ratings on the stocks aren't great, but Zacks has given it a HUGE Earnings Surprise Prediction (13.25%!), which should help the stock continue its run until the next report date in early August. Be aware, however, that it is approaching some stiff resistance above $4.60. It should rise Monday, but then it...
Pattern: $84-$90 support has proven itself a multiple times. Stock is in a medium term consolidation pattern between $85 to $130 range. Edge: Buying so close to or right at support gives us a great reward to risk ratio. If the stock breaks below support, we are stopped out for a small loss, but if support is protected again, we have more higher upside. Risk...
Today we gonna look at the pharmaceutical company, as a potential new giant trend on the stock market. NASDAQ:BMRN laying on the strong support line near $87.87 and can move up suddenly. My recommendation: 1. Buy now around 87.87 2. Take profit: 109.45 3. SL: 78.68 Risk/Reward - 2.39, potential profit - 24,6%
Another pharma company - with amazing correct Elliot 5 waves which you can try to ride. 1. Buy 131.32 2. Take profit: 213 3. SL: 115.90 RISK/REWARD: 5.38, potential profit 62.39%
Here we can see that for the past INTERCEPT PHARMACEUTICALS INC has been finding support at around in around $87, which has been confirmed 5 times, and a resistance of about $116-$120, which is a little less defined but just looking at the chart, it is there. Once the pattern proves itself that price action is going bull up to support, that's when I will go long....
target 1: $3.70 - 3.94 lets see how the next 2 weeks play out (some time around 4/24/2019)
CVS Health Corporation is american stock pharmacy operator offering nice sell opportunities at new supply imbalances created on both the weekly and the monthly timeframes with everything pointing down in a clear downtrend with new supply levels being created and demand levels being eliminated. Strong imbalances created on the way down.Two new supply levels have...
Biogen has lost over 30% of its value this month. Looking at the monthly chart, we have concluded that this is a rare investment opportunity as the current price is just above its 1M Support Zone. Historically we see that such an aggressive sell off recently took place in 2015 - 2016 and again the stock managed to recover almost reaching the 390 Resistance...